FDAnews
www.fdanews.com/articles/84871-vical-s-ebola-drug-shows-promise

VICAL'S EBOLA DRUG SHOWS PROMISE

February 27, 2006

In a Phase I trial, Vical's Ebola vaccine candidate, administered using the company's proprietary DNA-delivery technology, was shown to be safe and well-tolerated. The candidate was also shown to produce both antibody and T-cell Ebola-specific responses in all healthy volunteers who received the full three doses of vaccine.

The randomized, placebo-controlled, dose-escalation study, the first human trial for any Ebola vaccine, was sponsored by the National Institutes of Health (NIH), and conducted at the NIH Clinical Center.